Abbott Diagnostics

Gold

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more

Abbott Highlights Rapid Diagnostic Platforms to Complement Centralized RT-PCR Testing at ECCMID 2022

By LabMedica International staff writers
Posted on 26 Apr 2022

Image: ID NOW Molecular Platform (Photo courtesy of Abbott)

Abbott (Lake Forest, IL, USA) participated in ECCMID 2022 where it highlighted its range of rapid diagnostic platforms that complement centralized RT-PCR testing as well as empowers labs to efficiently and cost-effectively extend their impact throughout hospitals.

Abbott’s product portfolio exhibited at ECCMID 2022 included ID NOW, a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The company’s ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing healthcare professionals to make effective clinical decisions sooner. Abbott demonstrated its Panbio COVID-19 Ag Rapid Test Device that can identify potentially contagious patients with or without symptoms in 15 minutes alongside its Panbio COVID-19 IgG/IgM Rapid Test Device for the qualitative detection of IgG and IgM antibodies to SARS-CoV-2 in human serum, plasma, venous and fingerstick whole blood.

In addition, Abbott demonstrated its Afinion CRP rapid in vitro diagnostic test for the quantitative determination of C-reactive protein (CRP) in human blood in three minutes. Afinion CRP helps reduce diagnostic uncertainty and guides antibiotic decision-making during the patient’s visit. A significantly increased CRP result may indicate the need for immediate antibiotic treatment. CRP Point of care testing has been shown to reduce antibiotic prescribing by more than 60% if combined with communication training for general practitioners. The test runs on Abbott’s Afinion2 Analyzer, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the point-of-care. With the Afinion System, there’s no need to send patients to the lab or spend time tracking down their results.

Related Links:
Abbott